A brief history of novel drug discovery technologies

Nature Reviews Drug Discovery

Volumn 2, Issue 4, 2003, Pages 321-327

  Gershell, Leland J ^a   Atkins, Joshua H ^a  

^a AGW BioStrategy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; AMPRENAVIR; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; BROMFENAC; CARVEDILOL; CERIVASTATIN; CISAPRIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL MALEATE; ENDOTHELIN RECEPTOR ANTAGONIST; INSULIN; NEFAZODONE; NELFINAVIR; NEW DRUG; OMALIZUMAB; OMAPATRILAT; PROTEINASE INHIBITOR; RAPACURONIUM BROMIDE; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; SPIRONOLACTONE; TERFENADINE; TROGLITAZONE; TROVAFLOXACIN; UNINDEXED DRUG; VALSARTAN; ZILEUTON;

ALLERGY; ARTICLE; ASTHMA; BIOTECHNOLOGY; BRONCHOSPASM; CONGESTIVE HEART FAILURE; DEPRESSION; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG APPROVAL; DRUG INDUSTRY; DRUG RESEARCH; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INFECTION; IRRITABLE COLON; ISCHEMIC COLITIS; LIVER TOXICITY; MEDICAL GENETICS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; NONHUMAN; PAIN; PHARMACOGENOMICS; PRIORITY JOURNAL; RHABDOMYOLYSIS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; HISTORY;

ANIMALS; BIOTECHNOLOGY; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG INDUSTRY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MODELS, MOLECULAR;

EID: 0037395605     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1064     Document Type: Article

References (38)

1. Merrifield, R. B. Solid-phase syntheses (Nobel lecture). Angew. Chem. 97, 801-812 (1985).
2. Elmblad, A. et al. Synthesis of mixed oligodeoxyribonucleotides following the solid phase method. Nucleic. Acids Res. 10, 3291-3301 (1982).
3. Bunin, B. A. & Ellman, J. A. A general and expedient method for the solid-phase synthesis of 1,4-benzo-diazepine derivatives. J. Am. Chem. Soc. 114, 10997-10998 (1992).
4. Day, K. Testing a combination punch against disease. The Washington Post (Washington) (April 14, 1996).
5. Dolle, R. E. Comprehensive survey of combinatorial library synthesis: 2000. J. Comb. Chem. 3, 477-517 (2001).
6. Arya, P. et al. Toward high-throughput synthesis of complex natural product-like compounds in the genomics and proteomics age. Chem. Biol. 9, 145-156 (2002).
7. Sears, P. & Wong, C.-H. Toward automated synthesis of oligosaccharides and glycoproteins. Science 291, 2344-2350 (2001).
8. Wess, G. How to escape the bottleneck of medicinal Chemistry. Drug Discov. Today 7, 533-535 (2002).
9. Auld, D. S. et al. Targeting signal transduction with large scale combinatorial collections. Drug Discov. Today 7, 1206-1213 (2002).
10. Hughes, D. Therapeutic antibodies make a comeback. Drug Discov. Today 3, 439-442 (1998).
11. Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975).
12. To, A. et al. Monoclonal antibodies: present and future. Credit Suisse First Boston Corporation (2000).
13. Schmeck, Jr, H. M. Gene studies emerging as key engine of science. The New York Times (September 6, 1988).
14. Debouck, C. & Metcalf, C. The impact of genomics on drug discovery. Annu. Rev. Pharmacol. Toxicol. 40, 193-208 (2000).
15. Zambrowicz, B. P. & Sands, A. T. Knockouts model the 100 best-selling drugs - will they model the next 100? Nature Rev. Drug. Discov. 2, 38-51 (2003).
16. Schmitt, C. A. & Lowe, S. W. Apoptosis and chemoresistance in transgenic animal models. J. Mol. Med. 80, 137-146 (2002).
17. De Angelis, F. G. et al. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of axon 51 of the dystrophin pre-mRNA induce axon skipping and restoration of a dystrophin synthesis in Δ 48-50 DMD cells. Proc. Natl Acad. Sci. USA 99, 9456-9461 (2002).
18. Specter, M. Computer is drug design's new mortar and pestle. Washington Post (December 17, 1988).
19. Whittaker, M. et al. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 99, 2735-2776 (1999).
20. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol, Methods 44, 235-249 (2000).
21. Bemis, G. W. & Murcko, M. A. Properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 39, 2887-2893, (1996).
22. Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537 (1999).
23. Scherf, U. et al. A gene expression database for the molecular pharmacology of cancer. Nature Genet. 24, 236-244 (2000).
24. Kodadek, T. Protein microarrays: prospects and problems. Chem. Biol. 8, 105-115 (2001).
25. Gerhold, D. L. et al, Better therapeutics through microarrays. Nature Genet. 32, 547-551 (2002).
26. Hodgson, J. ADMET - turning chemicals into drugs. Nature Biotechnol. 19, 722-726 (2001).
27. Ekins, S. & Rose, J. In silico ADME/Tox: the state of the art. J. Mol. Graph. Model 20, 305-309 (2002).
28. Schmitt, C. A. & Lowe, S. W. Apoptosis and chemoresistance in transgenic animal models, J, Mol. Med. 80, 137-146 (2002).
29. Zhang, J. et al. Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 298, 422-424 (2002).
30. Tarbit, M. H. & Berman, J. High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. Curr. Opin. Chem. Biol. 2, 411-416 (1998).
31. Lipinski, C. A. et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-25 (1997).
32. Beresford, A. P. et al. The emerging importance of predictive ADME simulation in drug discovery. Drug Discov. Today 7, 109-116 (2002).
33. Craigie, R. HIV integrase, a brief overview from chemistry to therapeutics. J. Biol. Chem. 276, 23213-23216 (2001).
34. Klapholz, M. Emerging therapies in heart failure. Cardiol. Spec. Ed. 7, 71-74 (2001).
35. Michels, D. A. et al. Fully automated two-dimensional capillary electrophoresis for high sensitivity protein analysis. Mol. Cell. Proteomics 1, 69-74 (2002).
36. Perkel, J. M. Tissue microarrays: advancing clinical genomics. The Scientist 21, 39 (2002).
37. Cornish, V. & Tao, H. Y. Milestones in directed enzyme evolution. Curr. Opin. Chem. Biol. 6, 858-864 (2002).
38. James, W. Nucleic acid and polypeptide aptamers: a powerful approach to ligand discovery. Curr. Opin. Pharmacol. 1, 540-546 (2001).